| TUPEA08 | Potent, HIV-specific latency reversal through CRISPR activation delivered by lipid nanoparticles exhibiting a high efficiency of transfecting resting CD4+ T cells with minimal toxicity | Poster exhibition | Understanding and targeting persistent HIV reservoirs |
| TUPEA09 | Characterization of the intact and defective HIV-1 subtype C reservoir in South African women and men at baseline and 96 weeks after ART-therapy | Poster exhibition | Understanding and targeting persistent HIV reservoirs |
| TUPEA10 | Methylseleninic acid induces HIV viral reactivation from latently infected cells in vitro and ex vivo | Poster exhibition | Understanding and targeting persistent HIV reservoirs |
| TUPEA11 | DPP9 inhibitors: a novel class of drugs for clearance of HIV-1 infected cells | Poster exhibition | Novel treatment and prevention strategies |
| TUPEA12 | Pre-existing immunity restricts plasma and mucosal antibody responses during SARS-CoV-2 Omicron breakthrough infection | Poster exhibition | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| TUPEA13 | Immunological profiles of people living with HIV admitted with acute COVID-19 in Tshwane, South Africa | Poster exhibition | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |
| TUPEB01 | Association of antiretroviral therapies with adverse perinatal outcomes in pregnant women living with HIV: systematic review and meta-analysis | Poster exhibition | Antiretroviral therapies and clinical issues in adults |
| TUPEB02 | Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing: week 24 results of the randomized D2ARLING study | Poster exhibition | Antiretroviral therapies and clinical issues in adults |
| TUPEB03 | Efficacy and safety of switching older adults (≥60 years) from first-line art to B/F/TAF in Kenya - a randomized clinical trial (the B/F/TAF elderly study) | Poster exhibition | Antiretroviral therapies and clinical issues in adults |
| TUPEB04 | Similar inflammatory markers after switching to cabotegravir + rilpivirine long-acting vs. continuing bictegravir/emtricitabine/tenofovir alafenamide: data from the Phase 3b SOLAR study | Poster exhibition | Antiretroviral therapies and clinical issues in adults |